Last updated on February 2018

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)


Brief description of study

This is an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer).

Patients will be recruited from participating sites in Europe, Asia, and Canada. The study will include 2 patient cohorts.

Detailed Study Description

Study Design This will be an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer).

Patients will be recruited from participating sites in Europe, Asia, and Canada. Patients meeting the study inclusion/exclusion criteria will be selected during a 24-month enrolment period per country and will be followed from enrolment in the study until death, loss to follow-up, withdrawal of consent or study end date (whichever occurs earlier). Data Sources Data will be collected following enrolment in the study and entered in the electronic case report form (eCRF). All data will be collected using patient medical records. The investigator will be responsible for ensuring that all the required data is collected and entered into the eCRF. The site will collect the patient questionnaires and the data will be uploaded according to the data entry procedures.

Study Population

  • Adult male or female patients (according to age of majority/adulthood as defined by local regulations) who have given written informed consent as per local regulations.
  • The primary cohort will include patients with EGFR (epidermal growth factor receptor) mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI (tyrosine kinase inhibitors) therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
  • Additionally, a secondary cohort of patients will include patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.

Exposures There are no specific drug exposures or interventions being evaluated, as cohort eligibility (for both cohorts) is not exposure-based, but rather disease-based. All molecular testing and treatments will be at the discretion of the treating physician. Study Measures and Outcomes

  • Patient demographic and clinical characteristics
  • Molecular testing patterns and outcomes
  • Treatment patterns
  • Physician-reported clinical outcomes
  • Cancer-related health care utilization
  • Treatment- and biopsy-related complications
  • CNS metastases (brain metastases and leptomeningeal metastases) and treatments associated with CNS (central nervous system) metastases
  • HRQoL (Health Related Quality of Life) and symptoms Precision and Sample Size Estimations For the primary cohort the minimum sample size recommended for conducting a country-level analysis is 200 patients per country. This is based on the precision estimation calculation for the categorical study measure (% of patients tested) and will allow a maximum of
    • 8.3% precision (i.e., assuming 50% undergoing molecular testing) around the point estimate for the categorical measure. For the secondary cohort the minimum sample size recommended for conducting a country-level analysis is 300 patients which was determined using precision estimates calculated for a categorical (% of patients tested) and a time-to-event (overall survival) measure. The overall study will include approximately 2800-3300 patients across all participating countries across both primary (1200-1300 patients) and secondary (1600-2000 patients) cohorts. Statistical Analysis No formal hypothesis testing is specified. Study measures including patient demographics and clinical characteristics, molecular testing patterns, treatment sequence patterns, physician-reported outcomes (overall survival) and patient-reported outcomes (HRQoL) will be reported by primary and secondary cohorts, unless indicated otherwise. Continuous study measures (e.g., age, duration of therapy) will be reported descriptively with mean, standard deviation, median, minimum and maximum. Frequencies and percentages will be used to document categorical measures of interest (e.g., number and proportion of patients with a post progression molecular test, number and proportion of patients with a T790M mutation) and will include 95% CIs for key outcome variables. Kaplan-Meier curves and median survival will be estimated, overall and on an exploratory basis by clinical and treatment characteristics of interest (provided there are sufficient events available; e.g., chemotherapy vs. targeted therapy) as pre-specified in the statistical analysis plan.

Clinical Study Identifier: NCT03053297

Find a site near you

Start Over

Research Site

Winnipeg, MB Canada
  Connect »

Research Site

Moncton, NB Canada
  Connect »

Research Site

HaLifax, NS Canada
  Connect »

Research Site

Hamilton, ON Canada
  Connect »

Research Site

Kingston, ON Canada
  Connect »

Research Site

London, ON Canada
  Connect »

Research Site

Markham, ON Canada
  Connect »

Research Site

Newmarket, ON Canada
  Connect »

Research Site

Thunder Bay, ON Canada
  Connect »

Research Site

Toronto, ON Canada
  Connect »

Research Site

Montreal, QC Canada
  Connect »

Research Site

Guangzhou, China
  Connect »

Research Site

Aix En Provence, France
  Connect »

Research Site

Tours Cedex 9, France
  Connect »

Research Site

Metz-Tessy, France
  Connect »

Research Site

Suresnes, France
  Connect »

Research Site

Nantes Cedex 2, France
  Connect »

Research Site

Saint Nazaire, France
  Connect »

Research Site

Saint Priest En Jarez, France
  Connect »

Research Site

Angers Cedex 9, France
  Connect »

Research Site

Marseille, France
  Connect »

Research Site

Villefranche-sur-Saone, France
  Connect »

Research Site

Le Mans cedex 9, France
  Connect »

Research Site

Brieuc Cedex 1, France
  Connect »

Research Site

Cannes CEDEX, France
  Connect »

Research Site

Chambery, France
  Connect »

Research Site

Clermont Ferrand, France
  Connect »

Research Site

La Reunion, France
  Connect »

Research Site

La Rochelle Cedex, France
  Connect »

Research Site

Libourne, France
  Connect »

Research Site

Mantes la Jolie, France
  Connect »

Research Site

Montfermeil, France
  Connect »

Research Site

Mulhouse, France
  Connect »

Research Site

Paris Cedex 14, France
  Connect »

Research Site

Poitiers Cedex, France
  Connect »

Research Site

Rennes, Cedex 9, France
  Connect »

Research Site

Saint-Pierre, France
  Connect »

Research Site

Saint-Quentin, France
  Connect »

Research Site

Strasbourg, France
  Connect »

Research Site

Toulouse Cedex 9, France
  Connect »

Research Site

Palma de Mallorca, Spain
  Connect »

Research Site

Jerez de la Frontera, Spain
  Connect »

Research Site

Las Palmas de Gran Canaria, Spain
  Connect »

Research Site

Majadahonda, Spain
  Connect »

Research Site

Pozuelo de Alarcon, Spain
  Connect »

Research Site

Barcelona, Spain
  Connect »

Research Site

Pontevedra, Spain
  Connect »

Research Site

Whitchurch, United Kingdom
  Connect »

Research Site

Hull, United Kingdom
  Connect »

Research Site

Brighton, United Kingdom
  Connect »

Research Site

Maidstone, United Kingdom
  Connect »

Research Site

Wirral, United Kingdom
  Connect »

Research Site

Birmingham, United Kingdom
  Connect »

Research Site

Bristol, United Kingdom
  Connect »

Research Site

Camberley, United Kingdom
  Connect »

Research Site

Glasgow, United Kingdom
  Connect »

Research Site

Ipswich, United Kingdom
  Connect »

Research Site

Leeds, United Kingdom
  Connect »

Research Site

Manchester, United Kingdom
  Connect »

Research Site

Newcastle Upon Tyne, United Kingdom
  Connect »

Research Site

Nottingham, United Kingdom
  Connect »

Research Site

Scunthorpe, United Kingdom
  Connect »

Research Site

Sheffield, United Kingdom
  Connect »

Research Site

Wolverhampton, United Kingdom
  Connect »

Research Site

Worcester, United Kingdom
  Connect »

Research Site

San Cristobal de La Laguna, Spain
  Connect »

Research Site

Taichung, Taiwan
  Connect »

Research Site

Changhua, Taiwan
  Connect »

Research Site

Kaohsiung, Taiwan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.